AI Summary
→ WHAT IT COVERS Kenneth Galbraith, CEO of Zymeworks, explains how the company built a portfolio of five pharma partnerships using its Azymetric bispecific antibody platform, secured a $375M Jazz Pharmaceuticals deal for zanadetimab, and pivoted in November 2024 toward a hybrid royalty acquisition model to compound returns without building internal commercialization infrastructure. → KEY INSIGHTS - **Royalty-weighted deal structure:** When negotiating partnerships, prioritize downstream royalties and milestones over headline upfront payments. Zymeworks accepted $375M upfront from Jazz in 2022 — equal to its entire market cap at the time — while retaining royalty rights that became substantially more valuable after zanadetimab's FDA accelerated approval and positive Phase 3 gastric cancer data in 2024. - **Open-access platform validation strategy:** Rather than partnering exclusively with one pharma company, Zymeworks licensed its Azymetric design platform non-exclusively to multiple partners — GSK, Lilly, Daiichi Sankyo, J&J — retaining financial stakes in each resulting product. J&J's pazritamig, designed on Azymetric, has now entered multiple Phase 3 trials, generating milestone payments without Zymeworks funding development. - **China partnership for clinical scale:** To access HER2-expressing gastric cancer patient populations in Asia, Zymeworks partnered with BioGene (now BioNTech subsidiary B1) in 2017 specifically for China clinical operations — a market where running independent trials is operationally prohibitive. This accelerated zanadetimab's global development timeline and secured commercial coverage across three continents via two partners. - **Hybrid capital allocation model:** Zymeworks now allocates capital across three parallel tracks: internal R&D focused on trispecific antibodies and ADCs, external asset acquisition for in-house development and re-partnering, and direct royalty stream purchases on late-stage assets invented and licensed by others. Hiring a Chief Investment Officer in November 2024 signals the royalty acquisition track is being built as a distinct business unit. - **Ten-year development cycle management:** Biotech leaders must plan for capital market cycles, talent retention, and partner focus shifts that rarely align with decade-long drug development timelines. Galbraith recommends structuring partnerships and financial arrangements to accommodate investor liquidity needs mid-cycle, rather than assuming continuous capital availability — a lesson drawn from building QLT into a two-product global company over 13 years. → NOTABLE MOMENT Galbraith reveals that when Zymeworks first approached Merck to validate its Azymetric platform around 2007, Merck handed over a project they had already failed internally — with little expectation the small Vancouver company would succeed. That successful result became the proof point used to open partnerships with GSK, Lilly, Daiichi Sankyo, and J&J. 💼 SPONSORS None detected 🏷️ Bispecific Antibodies, Royalty Financing, Biotech Partnerships, HER2 Oncology, Drug Commercialization Strategy